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1. Introduction
Unmet need. It is beyond dispute that human population is ageing. For the first time in history,
people age 65 and over will outnumber children under age 5. This trend is emerging around
the globe, and will bring several challenges for health technologies. For instance, in a few
decades, the loss of health and life worldwide will be greater from chronic diseases than from
infectious diseases and accidents [4].
The report made by the National Institute of Health and the National Institute of Aging (NIH/
NIA) underscores the unmet needs lying ahead for regenerative medicine. Chronic diseases,
in opposition to infectious diseases, are mainly treated by regenerative approaches, instead of
immunization and antibiotics.
Actually, many of those challenges are already present in our daily living: malformations
[9,14], accidents [16], chronic infections [9,15], and end-organ failure [17] (usually occurs
during the final stages of degenerative and other diseases), may, in some cases, only be treated
by organ replacement. In fact, end-organ failure alone already affects millions of Americans.
More specifically, nearly six million Americans suffer from heart failure with approximately
550,000 new cases diagnosed annually, 530,000 Americans suffer from end-stage renal disease
and nearly 25 million Americans suffer from chronic obstructive pulmonary disease with an
estimated 12 million new annual diagnoses [5]. As already stated, for many of those patients,
organ transplantation is their only treatment option. Currently, organ transplantation is
considered the best option for some patients and achieves up to 98,5% of patient 1-year survival
rates [18]. Unfortunately, though, current organ shortage/recovering engenders waiting lines
of up to three or more years [5]. During 2008, for instance, the number of heart transplantations
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decreased 2,67%, even though waiting lines increased during the same year. Such decrease
occurred mainly due to a reduction in number of recovered organs [18].
It is clear that alternatives to organ transplantation need to be developed as soon as possible.
That`s where tissue engineering comes into picture.
Tissue engineering. Tissue engineering refers to an “interdisciplinary field that applies the
principles of engineering and the life sciences toward the development of biological substitutes
that restore, maintain, or improve tissue function” [3]. The term was first coined by Dr. Fung,
from California University, which suggested this name during the National Science
Foundation Meeting, in 1987 [2]. The first official definition dates to 1988, though, when Skalak
and Fox published it after the “Tissue engineering Meeting” held in Lake Tahoe, USA during
that year [1].
In 1993, Langer and Vacanti described three strategies for the creation of new tissue in vitro [3].
1. Isolated cells or substitutes. The concept of treating injured tissues with isolated cells is
currently regarded as cell therapy. Infusion of cells, e.g. stem cells, has presented several
promising results, and have already been approved for human use for specific
applications [21] but in some cases, is hindered by the lack of fixation of cells in the site
of lesion. When injected systemically, stem cells are attracted to injured tissues, but are
also found in several organs such as lungs, liver and spleen [56].
2. Tissue inducing substances. At the time, tissue inducing substances included growth factors,
small molecules, and other classes of molecules which, if delivered in the organism, would
promote several effects on cells, such as growth [58], survival [58], migration [57] and neo
tissue formation.
3. Cells placed on or within matrices. Associated cells and substrates provide the injured tissue
with continuity, and promotes cell attachment and fixation. In this context, scaffolds may
be associated with inducing substances, providing means to combine all the aforemen‐
tioned strategies. The combination of cells and matrices, in addition to inducing
substances or not, is currently the main strategy for tissue engineering, as depicted in
Figure 1.
Currently, tissue engineering focuses mainly of associating cells with supports (also called
biomaterials or scaffolds), in order to: i. promote cell attachment and restrict their distribution
in the tissue, ii. direct cell distribution and differentiation, iii. sustain large tissue losses while
new tissue is formed, and ultimately, to iv. lead to new tissue formation.
Since its early days, tissue engineering has significantly evolved in each of its pillars – Cells,
signaling molecules and scaffolds. This evolution covered both conceptual aspects - as
evidenced above – as well as practical aspects, mainly reflected in the achievements of the field
(for more information, go to conclusion section). Unfortunately, even though cells and
signaling molecules platforms have evolved during the past decades, leading to major field
evolution, the degree of success of tissue engineering methods is still highly dependent on the
properties of the scaffold. Therefore, this study focuses on the main Achille`s Hill of tissue
engineering: production of scaffolds for biological applications.
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Figure 1. Tissue engineering strategies. Based on [59]. Tissue engineering may be performed by several different ap‐
proaches, as proposed by Langer and Vancanti. In order to obtain tissue regeneration, cells, scaffolds and signaling
molecules may be introduced into the body alone or in association. Currently, the association of all three elements,
composing bioactive constructs, is proposed to be the best option for tissue engineering.
In the present chapter, we present the current status of tissue engineering. First, we present
a comprehensive picture of classical tissue engineering approaches, as well as an analytic
view of its main achievements and limitations. Secondly, we present innovative and para‐
digm breaking strategies for successful tissue engineering, accompanied by the history and
rationale behind each of them. Finally, we analyze the next steps of tissue engineering trans‐
lation into the clinic.
2. Classical tissue engineering approaches
Association of cells to classic biodegradable solid/porous biomaterial represents a dominat‐
ing conceptual framework in tissue engineering. Actually, men have used biomaterials
(alone, not associated to cells) in order to substitute eventual tissue loss since ancient civili‐
zations [11]. In the early days, all kinds of materials derived from natural and manufactured
sources were used as biomaterials. Natural materials included wood and shells, and manu‐
factured materials comprised metals such as iron, gold and zinc. The host responses to these
materials were extremely varied, and only after the concept of sterility, biomaterial implants
began to achieve consistent safety. During the last 30 years, further progress has been made
in understanding the interactions between the tissues and the materials.
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Since then, tissue reconstitution evolved to a more sophisticated approach, in which the regen‐
eration of the tissue/organ was clearly viewed as the ideal way of treating injuries, compared to
biomaterial science, which simply reconstitutes tissue structure, without restoring tissue func‐
tion in most situations. This paradigm evolution led to the emergence of tissue engineering.
Tissue engineering based on biomaterials relies on four main classes of materials: i. Poly‐
mers, ii. Ceramics, iii. Metals and iv. Composites (blends and combinations of the aforemen‐
tioned materials). Biomaterials may derive from natural or synthetic sources [12].
The association of cells to biomaterials is called construct and is the base of current tissue
engineering, as already stated. Construct-based classic tissue engineering platform derives
from several basic assumptions, as described by Mironov et al., 2009 [31]: “1) cell growth is
substrate attachment-dependent; cells need a solid substrate for attachment and prolifera‐
tion; 2) tissue constructs must have an organo-specific shape; a solid scaffold is essential to
keep the desired shape; a tissue construct could not maintain its shape without a solid rigid
scaffold; 3) the scaffold serves not only as an attachment substrate, but also as a source of
inductive and instructive signals for cell differentiation, migration, proliferation and orienta‐
tion; 4) the porous structure of a solid scaffold will allow optimal cell seeding, tissue con‐
struct viability, and vascularization; and 5) mechanical properties initially provided by the
rigid solid scaffold after its biodegradation will be maintained by controlled neomorphogen‐
esis of parenchymal and stromal tissue synthesized in vitro or in vivo in the tissue construct”.
Considering these basic assumptions, currently, classic tissue engineering is made taking
several aspects into account, which will be highlighted below.
1. Construct design. Currently, scaffold design is a complex science, in which several aspects
are carefully addressed in order to produce successful constructs. Those aspects include,
but are not restricted to:
i. Choosing the most suitable biomaterial for the envisioned application. Organs and tissues
in the human body present different characteristics, therefore, the ideal biomaterial
must reproduce as many as those features as possible. Such aspects include tissue
resistance, elasticity, resilience, and chemical composition, among others, in addition
to biocompatibility. For instance, a biomaterial designed to be used in a skin construct
must be thin and elastic. A biomaterial for application in corneas, on the other hand,
must also be thin, but most importantly, it must be transparent.
ii. Customizing the material in order to promote cell colonization. The ideal construct must
promote rapid and equal cell adhesion and colonization, therefore scaffolds are usually
porous and present a surface which is recognized directly or indirectly (by promoting
protein adsorption) by the cell as a substrate for attachment. Usually, materials such as
chitosan and collagen are used as biomaterials,  due to their  resemblance to the
extracellular matrix and their efficacy in promoting cell adhesion [26,27]. In case of other
materials, such as metals and ceramics, biomaterial surface may not be easily recognized
by cells. In order to improve cell contact and adhesion by cells, many strategies have
been developed, such as blending biomaterials, recovering them with other substances
or still covering them with protein residues recognized by cells, such as isoleucine-
lysine-valine-alanine-valine (IKVAV) residue, derived from Laminin [28,29].
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iii. Studying material tribology and surface topography [19]. For several tissues, such as
muscles and tendons, cell organization is paramount for optimal tissue function. The
heart, for instance, works as a pumping organ, and needs to contract in a specific,
synchronized way in order to actually eject blood into body and lungs. If muscle fibers
are not synchronized, no pumping force is generated, and great deficit of function is
witnessed by the patient [60]. Tendon is a specific connective tissue composed of
parallel collagen fibers. Along with the heart, tendon constitutes another of several
tissues which depend on specific cell organization for proper function. It has been
thoroughly described in literature that tendon strength is directly linked to cell
orientation, and, following injuries, the lack of orientation of scar tissue promotes
tendon weakness, leading to repetitive lesion [61]. Tissue engineering approaches for
tendon must promote cell alignment in order to achieve significant benefit for
patients. cell alignment has been shown to be achievable and effective in promoting
tissue organization and maturation [30], as shown in Figure 2.
iv. Optimizing biomaterial degradation rate. Tissue engineering has been envisioned to
promote tissue regeneration, therefore in this context, biomaterials should be
biodegradable. Ideally, biomaterial should gradually degrade, at the same rate as
neotissue is formed.
Figure 2. Cell orientation promotes major contractile strength of construct. In order to assess cell orientation impor‐
tance for construct function, Dr. Parker`s group engineered bidimensional cardiac muscles with different micropat‐
terned surfaces in order to promote degrees of cell orientation. Confluent unaligned isotropic (A), aligned anisotropic
(B) and non confluent, 20μm spaced, parallel arrays of myocardial fibers (C) were build and studied in vitro. The cited
work showed that contractile force increases with major sarcomere alignment, as measured by peak systolic stress in
kPa (D). This panel was based on [60] and was kindly provided by Dr. Kevin Kit Parker, from Harvard University.
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2. Cell seeding. Cell seeding is paramount for construct optimization, and must be carefully
planned. Usually, most cells have low capacity of invasion, therefore, cell seeding must
be  optimized to  promote  an  equal  distribution of  cells  along construct  surface  and
interior [62].
3. Construct maintenance in vitro. The maintenance of small constructs may be achievable in
static cultures, but when it comes to larger constructs, static culture is hindered by the
limitation of nutrient diffusion. Several strategies have been developed for large construct
maintenance in vitro, represented mainly by bioreactors, as depicted in Figure 3.
Figure 3. Importance of non-static cell seeding and culture for construct equal distribution of cell elements and viabili‐
ty of construct. As depicted, static culture seeding promotes cell accumulation in specific regions of the construct. As
no media is perfused through the construct, nutrient distribution along the biomaterial depends on diffusion only,
which leads to normoxic construct edges, colonized with cells and hypoxic center, which is not feasible to be colon‐
ized by cells. Nonstatic culture strategies, on the other hand, promote equal cell seeding and colonization of the con‐
struct, as it enhances nutrient diffusion. Even though nonstatic culture is not sufficient to promote viability of large
constructs, it increases maximum size of constructs and is more adequate for tissue engineering purposes.
4. Construct implant. The ultimate function of a construct built in vitro is to be implanted and
substitute/regenerate an injured organ or tissue. Construct implant must be performed in
order to promote construct integration and viability. Several techniques have already been
applied to promote construct long term viability, such as designing VEGF (vascular
endothelial growth factor) releasing constructs; previously implanting the construct in an
ectopic site, in order to promote in vivo vascularization, prior to implantation; and
reducing the size of implants, among others.
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In spite of its major advances, scaffold-based tissue engineering suffers from several
limitations, as explored by Mironov et al., 2009 [31], and further explained here:
1. Vascularization of thick tissue constructs
Cell survival requires continuous supply of nutrients and oxygen, as well as the removal of
metabolites, which, if accumulated, might be toxic. Such demand is addressed mainly by
osmosis, therefore, to facilitate nutrient and metabolite flow, cells must be kept near vessels
and capilars. Actually, few cells are able to survive at more than 200um distance from the
nearest blood vessel [8]. Cells cultured in tridimensional scaffolds also need to be maintained
in homeostasis in order to survive. In vitro, several strategies have been developed in order to
maintain construct viability prior to implantation, mainly through the development of
bioreactors, as reviewed by Rauh et. al. [10]. In vivo, however, none of those strategies are
applicable, and only through vascularization cells are kept alive, especially for modular
organs, such as heart, kidney and liver, which are organized in functioning units and require
their own vascular supply [9]. Studies indicate that vessels grow at a rate of <1mm a day [6],
and although the effectiveness of an enhanced angiogenic response using various growth
factors has been demonstrated in many tissue systems, the rate of angiogenesis hasn`t been
accelerated so far [7]. Considering the relatively large sizes of constructs for humans, it is clear
the urgent need to promote faster vascularization of tissue constructs, or to improve cell
survival in scaffolds.
Actually, several attempts of increasing tissue vascularization are underway.
As previously mentioned, increasing cell survival is also an interesting strategy. Actually,
recently, oxygen generating scaffolds have been developed and tested with encouraging
results, even though no in vivo tests were performed [7].
2. Precise placing of different multiple cell types inside 3D porous scaffolds is technologi‐
cally challenging.
Modular organs, such as the heart, liver, kidneys and others, are complex structures of several
types of cells, including stromal and parenchymal cells. They function as working units, such
as muscle fibers, liver lobules and kidney nephrons. Modular organs also count on intrinsic
vascular system for cell survival, constituting incredibly difficult organs to build in vitro, even
though many papers have shown a significant capacity of self-organization of several cells
[22,23,24]. For such organs, whole organ approaches are more suitable then partial
reconstitution of those structures.
On the other hand, non-modular organs have witnessed several successful strategies, such as
the construction of bladders [44] and the recellularization of tracheas [15], both of which have
already been translated to the clinic.
3. Achieving organo-specific level of cell density in tissue constructs remains a big challenge
Currently,  porous matrices are paramount to allow cell  invasion and colonization of the
matrix. Porous present in the matrices are usually optimized to have specific sizes and to
be  interconnected,  in  order  to  permit  cell  invasion.  The  size  of  the  produced porous  is
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usually large, though, and cells within the scaffold are not able to fully fill it and achieve
cell density similar to natural tissues. Therefore, it  is almost as if  cells were still  in two-
dimensional  surfaces  [31].  Actually,  extracellular  matrix  molecules  can  be  washed  out
from 3D porous scaffolds in the same way as in 2D cultures, and may not provide means
for real tridimensional tissue formation.
4. Recent reports on the effect of matrix rigidity on (stem) cell differentiation can undermine
the value of solid rigid biodegradable scaffolds at least for certain tissue applications
[35-37]
Stem cell differentiation has traditionally employed cocktails of various growth factors, but
recently, mechanobiological concepts have been described as important to cell fate decision.
The mechanism underlying cellular response to tension comprises the force generated by
myosin bundles sliding along actin filaments and transmission to the ECM. Transduction of
these signals link the extracellular and intracellular worlds, ultimately affected by proteins
such as Rho GTPases, which not only regulate contraction of stress fibers, but also regulate
gene expression by acting over their effector target proteins, [45].
Actually, matrix rigidity has been involved in embryonic development, as well as adult stem
cell differentiation. As expected, rigid surfaces facilitates adult stem cell differentiation into
bone, and soft surfaces lead to differentiation of adult stem cells into soft tissues, such as fat
or central nervous system (brain) [45].
5. Biodegradability of constructs
Even though it makes sense that biomaterials should be absorbed by the body in order to give
space to neotissue formation, the same is not true when whole tissue engineering is planned.
There is no use in spending efforts in order to build a construct, which will be invaded by
inflammatory cells and vessels and disorganized, previously to being substituted by neotissue.
Therefore,  even  though  current  tissue  engineering  techniques  are  fairly  successful  in
treating bone,  skin and cartilage loss,  they are extremely limited in treating large tissue
loss, as well as in regenerating complex tissues, such as heart annd kidneys, among sev‐
eral other tissues and organs.
3. Innovative tissue engineering approaches
3.1. Decellularized matrices
The Extracellular Matrix (ECM) represents the three-dimensional fibrilar protein scaffold,
produced by cells of each tissue and organ, which surrounds and anchors them. It is kept in a
state of dynamic reciprocity with those cells, in response to changes in the microenvironment.
ECM has been shown to provide cues that affect cell migration, proliferation, gene expression
and differentiation [32, 37].
The ECM is obviously the optimal support for tissue engineering, as it provides the perfect
chemical composition, surface topology and physical properties experienced by cells in vivo
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in their niche [32]. Even though sometimes that`s exactly what is needed to be avoided (e.g.
Central Nervous System ECM has been shown to contain molecules which inhibit axonal
growth and hinders tissue regeneration [33,34]), ECM has been considered a great option for
tissue engineering.
Recently, it has been shown that cell sensibility towards ECM chemical composition is higher
than previously expected. For instance, Tsai et al. showed that MG63, an osteoblast like cell
lineage, behaves differently when grown in collagen or gelatin electrospun matrices. When
grown in electrospun collagen, MG63 did not show variation on cell attachment or
proliferation rates. On the other hand, cells seeded on electrospun collagen showed increased
expression of osteogenic genes such as Osteopontin and alkaline phosphatase. Collagen and
gelatin present high chemical composition similarity, varying mainly in secondary and tertiary
structure. Such fact underscores the strikingly cell sensitivity to all aspects of ECM chemical
and physical composition [62]. It also underscores the potential of decellularized matrices on
tissue engineering.
Decellularized tissues have been used in regenerative medicine approaches since the early
eighties [38], specially focused on treating cardiovascular diseases by engineering vascular
grafts. Most of the grafts produced, derived from synthetic and natural sources suffered from
several limitations. When the issue of natural graft calcification and immunological recognition
were related to residual cellular components of unmodified biological materials, decellulari‐
zation techniques began to be developed [38,39].
Initially, decellularization was considered for tissue grafts. Developed techniques are con‐
tinuously  evolving,  as  every  cell  removal  agent  and  method  currently  available  alters
ECM composition and cause  some degree  of  ultrastructure  disruption.  Decellularization
agents  include  chemical,  biological  and  physical  agents,  each  of  them  with  different
mechanisms of action.
More specifically: acids and bases promote hydrolytic degradation of biomolecules; hypotonic
solutions lyses cells through osmosis with minimal changes in matrix molecules and tissue
architecture; hypertonic solutions dissociates DNA from proteins; ionic, non-ionic, and
zwitterionic detergents solubilize cell membranes leading to effective removal of cellular
material from tissue; solvents, such as alcohol and acetone, promote either cell lysis by
dehydration or solubilization and removal of lipids and biological agents, such as enzymes,
and chelating agents act through protein cleavage and disrupting cell adhesion to ECM.
Finally, physical agents promote cell lysis through freezing and thawing cycles, electropora‐
tion or pressure [32].
The most effective agents for decellularization of each tissue and organ will depend upon many
factors, including the tissue’s cellularity, density, lipid content, and thickness [32].
Lately, whole organ decellularization began to be performed, offering an interesting option
for modular organs such as the heart, lung and kidneys. In 2008, Ott et al. not only performed
whole heart decellularization, but also recellularized the organ with neonatal cardiomyocytes
and obtained organ function [17]. This groundbreaking work highlighted the possibilities of
decellularized matrix-based whole organ tissue engineering.
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The major breakthrough of organ decellularization is to obtain scaffolds with perfect (or very
similar) chemical composition and tridimensional structure, compared to natural organs. In
addition, the vascular bed is completely preserved, facilitating in vitro maintenance of the
construct via perfusion bioreactors, as well as in vivo viability of the construct, which may be
reconnected to the circulatory system of host, also shown by Ott et al [17]. As decellularization
is performed making use of vascular system of organs, virtually any vascularized organ may
be decellularized, disregarding its size, as depicted in Figure 4. Acellular organs, such as
tracheas, may also be decellularized through different protocols [15].
Figure 4. Decellularized pig heart. As published by Ott et al., perfusion decellularization is feasible in small rat organs,
but also in bigger size organs, such as the pig heart. Illustration owned by Miromatrix Medical Inc., available at http://
miromatrix.com/technology/perfusion-decellularization-recellularization/, accessed on September 2012.
3.2. Biomimetic scaffolds
As already mentioned, an optimal scaffold attempts to mimic the function of the natural
extracellular matrix [52]. The functionality of most tissues is related to their complex
architecture, therefore mimicking and recapitulating this complexity in vitro is paramount for
successful tissue engineering. In the in vivo condition, cells are surrounded by other cells and
by the extracellular matrix (ECM), whose components, such as collagen, elastin, and laminin,
are organized in nanostructures (i.e., fibers, triple helixes, etc) with specific bioactive motifs
that regulate cell homeostasis [42].
Following the initial concept of mimicking the ECM chemical composition, it has been shown
that the structure of the cell-surrounding niche is also paramount for optimal cell function. In
accordance, modulating the scaffold microarchitecture is one of the most potent ways of
Advances in Biomaterials Science and Biomedical Applications304
achieving biomimetic tissues. Advances in microfabrication technologies have been exploited
by an increasing number of research groups. Often technologies from other engineering
disciplines have been translated and used in creating microfeatures in engineered scaffolds in
a controlled manner. These include photolithographic approach of the electrical engineering,
electrospinning tools of the textile industry, emulsification and fluid dynamics principles of
chemical engineering and rapid prototyping methods of mechanical engineering. The latter
will be covered in further detail in the next section [40].
Vacanti and coworkers pioneered the concept of engineering a vasculature using photolitho‐
graphic techniques (which use light, e.g. UV, to selectively remove parts of a thin film or the
bulk of a substrate), literally generating channels within biomaterials [43].
Electrospining techniques have also been considered and tested for tissue engineering
application, due to their potential of producing polymer fibers with nano to micrometer
diameter scale that are physically and topographically comparable to the collagen fibers,
commonly found in the natural ECM, as shown in Figure 5. It has been extensively employed
in tissue engineering strategies, including vascularization strategies [41].
Figure 5. Similarity between ultrastructure of natural collagen fibers (A) and electrospun biomaterials (B). Source: A –
author`s unpublished data; B - http://en.wikipedia.org/wiki/Electrospinning, accessed on September 2012.
Electrospun biomaterials must also be carefully fabricated, as even fiber diameter variation
results in different cell behavior, as observed in endothelial cells cultured on electrospun
poly(l-lactide-co-ε-caprolactone) with different fiber diameters. In contrast to cells cultured on
fibers of 0.3 or 1.2μm, cells cultured on 7μm presented lower cell adhesion, spreading and
proliferation [63].
Even though electrospining has presented promising results, it also suffers from some
limitations, such as poor cell invasion, as usually the electrospun biomaterials are highly
compacted, impeding cell migration towards the inner side of the scaffold. The search for
different solvents and electrospining conditions may solve this issue, promoting less fiber
compactation.
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Still, as cited, many excellent constructs have been built using those techniques, and in
association with the other tissue engineering strategies presented in the present chapter,
strongly contribute to novel advances in the field.
Another exciting tissue engineering strategy, which have gained growing interest since the
nineties, has been the hydrogel approach. Hydrogels are 3D cross-linked insoluble,
hydrophilic networks of polymers that partially resemble the physical characteristics of native
ECM. The biocompatibility of various hydrogels (e.g., collagen, agarose and polyethylene
glycol) is well characterized, and the possibility of optimizing their physico-chemical and
mechanical properties to levels that are desirable for tissue scaffolds, in order to achieve cell
encapsulation, immobilization, and drug delivery turn hydrogels into an extremely promising
technique [64].
Hydrogels have been successfully used in mimicking ECM of simple tissues, composed of one
cell type. In many cases, hydrogels provide means for nutrient diffusion, facilitating cell
maintenance in vitro and in vivo. Still, maintaining the viability of high cell density constructs
remains a challenge as well as promoting cell organization within the scaffold. In many cases,
construct implantation near host rich vascularization sites may be an effective strategy to
promote construct viability in vivo.
In the cell`s point of view, hydrogels possess the advantage of completely surround
encapsulated cells, and providing tridimensional substrate for cell interaction. This strategy
prevents cell polarization which is common to regular scaffolds. Usually, as already stated,
even though most scaffolds may be tridimensional macroscopically, they are commonly seen
as bidimensional surfaces by cells.
As expected, truly tridimensional environments promote several effects over cultured cells.
Some of them include, but are not limited to: cell morphology/spreading [65], cell motility and
proliferation [66], and metabolic rate [67]. Obviously, all of those cell behaviors reflect
differential gene expression.
Even though cell gene expression is a paramount factor to be evaluated in tissue engineering,
it must be clearly noted that an exact gene expression profile is not essential for tissue
engineering effectiveness. Cells will always interact with their microenvironment. What is
important for tissue engineering is to maintain cell plasticity in a manner that, once in vivo,
implanted cells start to behave as host cells would.
Finally, a third highly modern and innovative approach for tissue engineering, which shares
the truly tridimensional environment for cells as provided by hydrogels, but which doesn`t
suffer from vascularization and cell organization limitations presented by the latter, is the
organ printing tissue engineering technique, which will be more thoroughly described in the
next section.
3.3. Organ printing
As listed before, the main limitations of the solid scaffold approach include the low level of
precision in cell placement, especially when engineering multicellular constructs, considering
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the intrinsic problem of vascularization of thick tissue constructs [53]. Ideally, a possible way
to solve many of those aforementioned problems would be to assemble cells and ECM elements
at the same time and in an organized way, in order to obtain the most similar structure found
in a functional organ as possible. Over the years, technology evolution turned tissue engineers
unreachable dream into a feasible objective to be fulfilled in the next years or decades. This
strategy is known as organ printing and/or robotic biofabrication, and offer interesting
alternatives to solid scaffold-based tissue engineering.
According to the First International Workshop on Bioprinting and Biopatterning, organ
printing was defined as “The use of material transfer processes for patterning and assembling
biologically relevant materials (molecules, cells, tissues, and biodegradable biomaterials) with
a prescribed organization to accomplish one or more biological functions” [45]. In fact, this
technology could be defined as computer-aided, layer-by-layer deposition of biologically
relevant materials [53].
The ultimate goal of organ-printing technology is to fabricate 3D vascularized functional living
human organs suitable for clinical implantation in reasonable time scales. Other applications
of this technology are in histogenesis and organogenesis, pharmacological tests and disease
research [45, 46, 47, 48].
Wilson and Boland (2003) showed protein and cell printing using a commercial ink-jet device
can be possible. In this technology, either individual cells or small clusters are printed over
ECM hydrogels, designed for involve printed cells and to provide them with desired signals.
Therefore, organ printing has derived from hydrogel classical approach, described in the
previous section. The method is rapid, versatile and cheap. Its disadvantage is that it is difficult
to assure high cell density needed for the fabrication of solid organ structures. Furthermore,
due to the high speed of cell deposition, considerable damage is caused to cells, although the
latest developments in the field have led to considerable improvement in cell survival [54,
55]. In the other approach, mechanical extruders are used to place ‘bio-ink’ particles,
multicellular aggregates of definite composition into a supporting environment, the ‘bio-
paper’, according to computer-generated templates consistent with the topology of the desired
biological structure. Organoids are formed by postprinting fusion of the bio-ink particles and
the sorting of cells within the bio-ink particles. The advantage of this technology is that the
bio-ink particles represent small 3D tissue fragments. Thus, cells in them are in a more
physiologically relevant arrangement, with adhesive contacts with their neighbors, which may
assure the transmission of vital molecular signals. Both inkjet and extruder bioprinting are
compatible with rapid prototyping [55].
In this biomanufacturing a precise layer-by-layer placement of self-assembled tissue spheroids
in sprayed tissue fusion permissive hydrogels is used to obtain an organ or tissue. The
hydrogels work as “biopapers” and cell blocks or tissue spheroids work as a “bioink”. Both
biopaper and bioink must be optimized in order to obtain viable tissues. For instance,
biopapers vary according to each “printed” organ, and cell spheroids vary in properties
according to their composition. Cell viability during and after printing is an obvious goal for
bioprinting [45]. Preliminary studies of both ink-jet and laser forward transfer indicated that
cells can survive deposition condition forces. Problems associated with ink-jet delivery of cell
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suspensions may also come about from the high shear stresses observed during ejection and
impact of a fluid drop [50, 51, 52].
In many cases, the bioprinting process requires that before and during printing, cells and
molecules must be carried in a fluid vehicle that shortly after printing requires consolidation
and should consequently behave as a viscoelastic solid. This phase change must occur without
damage to the biochemical, cells, or more complex units within the fluid, which presents a
considerable challenge. Concurrently, tissue printed mustn’t be too solid, or cell spheroids
won`t interact and form a continued tissue.
Organ printing is a technology that promises to transform tissue engineering into a
commercially successful biomedical industry. Unlike other tissue engineered approaches,
organ printing involves the high throughput generation of organs, relying on automated cell
sorters, cell and organ bioreactors and robotic bioprinters, most of them which are already
commercially available [46]. However, much research is necessary to turn this technology into
reality of clinical application.
4. Conclusion: Tissue engineering — From the bench to the bedside
It is known that any technology takes about 20 years to reach the market, and despite progress
in many fields, this timeframe has yet to shorten [20]. Accordingly, tissue engineering, which
has officially given its first steps during the late eighties, hasn`t brought many products to the
bedside [20].
In contrast to biomaterials - which are readily available as hip implants, contact lenses, silicon
breast prosthesis, among others –, and cell therapy – which is also available for bone marrow
transplants, as well as its first allogeneic stem cell therapy products [21] -, constructs have been
successfully produced for only few applications, largely limited to non-modular organs such
as skin epidermis, corneal epithelium and cartilage [40]. Indeed, Apligraf - a bilayered skin
substitute - was the first allogeneic cell based therapy to be approved by the US Food and Drug
Administration (FDA), receiving permission for sale as a treatment for venous leg ulcers13.
Apligraf is constructed by culturing human foreskin-derived neonatal fibroblasts in a bovine
type I collagen matrix over which human foreskin-derived neonatal epidermal keratinocytes
are then cultured and allowed to stratify [68]. Even though it is considered one of the first tissue
engineering products ever approved for commercialization, Apligraf doesn`t directly restore
skin, but transiently protects and provides injured skin with scaffold and signaling molecules
(produced by the cells within the construct) which fosters and accelerate skin regeneration.
Engineered bladders and airways have also been built and implanted in vivo, but as they
require highly customized and complex approaches, they are available to a small number of
patients, and are not considered products to be sold, such as Apligraf and other similar
products.
Therefore, it is clear that, in spite of recent advances, tissue engineering has much to deliver.
Innovative strategies, such as the presented in this chapter, present out of the box solutions
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for some of the present challenges in the field, and may one day constitute the major
breakthroughs to finally catalyze translating tissue engineering from bench to bedside.
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